CROT Antibody

What is CROT protein and why is it important in research?

CROT (Carnitine O-octanoyltransferase) plays a critical role in lipid metabolism, particularly in beta-oxidation of fatty acids. It demonstrates highest activity with C6 to C10 chain length substrates and converts 4,8-dimethylnonanoyl-CoA (the end product of pristanic acid beta-oxidation) to its corresponding carnitine ester . This peroxisomal transesterification is necessary for transport of medium- and long-chain acyl-CoA molecules from peroxisomes to cytosol and mitochondria . Understanding CROT function is essential for research on lipid metabolism disorders and related pathologies.

What types of CROT antibodies are available and how do they differ?

Several types of CROT antibodies are commercially available:

Research indicates that recombinant antibodies generally outperform both monoclonal and polyclonal antibodies across multiple assays . The specific choice depends on experimental requirements and application.

How should researchers validate CROT antibody specificity?

Proper validation is critical given that approximately 50% of commercial antibodies fail to meet basic standards for characterization . Best practices include:

• Using knockout (KO) cell lines as negative controls (gold standard)

• Testing in multiple applications (WB, IP, IF) with appropriate controls

• Confirming band appearance at expected molecular weight (70 kDa for CROT)

• Cross-validating with antibodies targeting different epitopes

The YCharOS initiative found that KO cell lines provide superior validation compared to other controls, particularly for immunofluorescence . Their analysis revealed that an average of ~12 publications per protein target included data from antibodies that failed to recognize the relevant target protein.

What is the optimal protocol for using CROT antibodies in Western blotting?

Western blotting protocols should be optimized based on the specific antibody:

For ab175450 (Abcam):

• Concentration: 1 μg/mL

• Primary incubation: 1 hour

• Detection: Chemiluminescence

• Expected band size: 70 kDa

For 13543-1-AP (Proteintech):

• Dilution: 1:10000

• Incubation: Room temperature for 1.5 hours

• Various lysates can be used, with liver tissue showing strong expression

Critical controls should include:

• Positive control (liver lysate)

• Negative control (preferably KO cell line)

• Appropriate loading controls

How should CROT antibodies be used in immunohistochemistry?

For paraffin-embedded tissues, demonstrated protocols include:

• Sample preparation: Formalin fixation and paraffin embedding of tissues

• Deparaffinization and antigen retrieval (method may vary by antibody)

• Blocking of endogenous peroxidases and non-specific binding

• Primary antibody incubation: 1:100 dilution for 13543-1-AP antibody (demonstrated in human liver cancer tissue)

• Detection system application (e.g., HRP-conjugated secondary antibody)

• Chromogenic development and counterstaining

Successful IHC staining has been demonstrated with CROT antibodies in both 10x and 40x magnification views of liver cancer tissues .

What are the proven conditions for immunofluorescence with CROT antibodies?

Based on validated protocols:

• Fixation: -20°C Ethanol demonstrated for HepG2 cells

• Blocking: Standard blocking solution

• Primary antibody: 1:400 dilution of 13543-1-AP

• Secondary antibody: CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L)

• Counterstaining for nuclei (DAPI recommended)

• Mounting and imaging with appropriate filters

CROT's peroxisomal localization should produce a distinctive punctate staining pattern in cells with high expression.

Can CROT antibodies be used in flow cytometry applications?

Yes, flow cytometry has been validated with CROT antibodies. For example:

• Sample preparation: 1x10^6 HepG2 cells

• Fixation and permeabilization (required for intracellular staining)

• Antibody concentration: 0.25 μg of 13543-1-AP

• Detection: CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L)

• Analysis: Standard flow cytometry protocols

Appropriate isotype controls and compensation settings are essential for accurate interpretation.

How can researchers distinguish between specific and non-specific binding of CROT antibodies?

Distinguishing specific from non-specific binding requires multiple validation approaches:

• Knockout validation: Using CROT KO cells provides the most stringent control

• Expression pattern analysis: CROT should show enrichment in tissues with high peroxisomal content (e.g., liver)

• Multiple antibodies comparison: Different antibodies targeting distinct epitopes should show similar patterns

• Peptide competition: Pre-incubating the antibody with the immunizing peptide should abolish specific signal

The YCharOS initiative has demonstrated that ~50-75% of proteins are covered by at least one high-performing commercial antibody, depending on the application . This indicates that despite concerns about antibody quality, reliable reagents exist when properly validated.

What considerations are important when designing experiments involving CROT and related metabolic proteins?

When studying CROT in the context of metabolic pathways:

• Consider its functional relationship with other proteins in fatty acid metabolism

• Account for tissue-specific expression patterns (highest in peroxisome-rich tissues)

• Evaluate experimental conditions that might alter lipid metabolism (fasting, high-fat diet, etc.)

• For multiplex studies, ensure antibody compatibility (host species, detection systems)

• Design appropriate controls for each specific application

For advanced studies, consider complementary approaches such as immuno-MRM (Mass Spectrometry) as mentioned in the RAS Initiative antibody development data .

How should researchers approach contradictory results from different CROT antibodies?

When facing contradictory results:

• Evaluate the validation data for each antibody (KO controls, multiple applications)

• Consider epitope differences (antibodies targeting different regions may give different results)

• Assess experimental conditions (fixation methods, extraction buffers) that may affect epitope accessibility

• Verify with orthogonal methods (mRNA expression, mass spectrometry)

• Review lot-to-lot variation information from vendors

The antibody characterization crisis highlighted in the literature emphasizes that rigorous validation is essential for reliable results .

How can CROT antibodies be integrated into targeted proteomics approaches?

For advanced quantitative studies of CROT:

• Immunoprecipitation followed by mass spectrometry (IP-MS)

• Immuno-MRM (Multiple Reaction Monitoring) for quantitative analysis

• Targeted proteomics using CROT-specific peptides

• Reverse Phase Protein Arrays (RPPA) for high-throughput analysis

The RAS Initiative dataset describes similar approaches for studying signaling network proteins, which can be adapted for CROT analysis .

What are common issues with CROT antibodies and how can they be addressed?

Common issues and solutions include:

The YCharOS study found that vendors proactively removed ~20% of tested antibodies that failed expectations and modified proposed applications for ~40% after rigorous testing .

How does sample preparation affect CROT antibody performance?

Sample preparation significantly impacts antibody performance:

• For Western blotting:

  • Extraction buffers affecting protein solubility

  • Denaturation conditions affecting epitope exposure

  • Reducing vs. non-reducing conditions

• For IHC/IF:

  • Fixation method (demonstrated success with -20°C ethanol for IF)

  • Antigen retrieval techniques

  • Section thickness

• For IP applications:

  • Lysis conditions preserving protein-protein interactions

  • Buffer compatibility with antibody binding

Optimize based on the specific antibody's validated conditions, as detailed in product documentation.

How can researchers ensure reproducibility when using CROT antibodies across different studies?

To ensure reproducibility:

• Document antibody details (catalog number, lot, dilution, incubation conditions)

• Include all validation controls in each experiment

• Standardize protocols across experiments

• Consider using recombinant antibodies for highest consistency

• Test new lots against previous lots before full implementation

• Share detailed protocols in publications

The antibody characterization crisis has been estimated to result in financial losses of $0.4–1.8 billion per year in the United States alone due to reproducibility issues .

What are the considerations for long-term storage and handling of CROT antibodies?

Proper storage and handling are essential:

Most manufacturers recommend:

• Storage at -20°C or -80°C upon receipt

• Avoiding repeated freeze-thaw cycles

• Following product-specific guidance for preservatives (e.g., 0.05% NaN3, 40% Glycerol in pH7.4 PBS)